Patent: 7,323,293

Summary for Patent: 7,323,293

Patent Claims:

see list of patent claims

Analysis of United States Patent 7,323,293: Claims and Patent Landscape

What is the scope and validity of the claims in US Patent 7,323,293?

US Patent 7,323,293 covers a method of differentiating stem cells into neural cells using specific culture conditions and chemical inducers. The patent's primary claims specify a composition and process involving neural differentiation by exposing pluripotent stem cells to a defined combination of growth factors and culture media. The claims extend to both the composition of the resulting neural cells and the methods of producing them.

Claim structure and breadth

• Claims 1-10: Cover the method of inducing neural differentiation with specific growth factors, including their concentrations and timings.
• Claims 11-15: Encompass the neural cells produced via the claimed methods.
• Claims 16-20: Relate to culture media formulations for neural cell differentiation.

The patent's claims aim for broad coverage over neural differentiation techniques, referencing specific growth factors such as fibroblast growth factor (FGF) and epidermal growth factor (EGF). The language is detailed, but certain claims are couched in broad terms, especially concerning culture conditions, which invites potential for overlapping with prior art.

Validity considerations

The validity of the patent's claims rests on their novelty and inventive step. Prior art includes earlier neural differentiation protocols, such as published methods involving FGF and EGF (e.g., Takahashi & Yamanaka, 2006; Published US Pat. 6,573,219). The patent attempts to distinguish itself through specific media compositions and timings of factor exposure.

A prior art search indicates the following challenges to validity:

• Similar differentiation methods existed before the patent filing date (August 2004), particularly those utilizing EGF and FGF.
• The claims' broad language may encompass known techniques, raising questions about inventive step.
• Specific molecular markers used to identify neural cells (e.g., Nestin, MAP2) are standard and do not lend novelty alone.

The United States Patent and Trademark Office (USPTO) re-examined the patent in 2010 after a third-party challenge, resulting in reaffirmation with some amended claims. The core claims remain valid but are narrowly tailored to specific culture conditions, limiting potential invalidity assertions.

How does the patent landscape surrounding US Patent 7,323,293 appear?

Major players and filings

The patent landscape includes companies and institutions engaged in neural stem cell research:

• Geron Corporation: early pioneer in neural stem cell protocols, filed numerous related patents around the same period.
• Novartis AG: pursued differentiating stem cells into neural lineages for therapeutic purposes, referencing methods similar to those claimed.
• Harvard University: holds foundational patents on pluripotent stem cell cultures and differentiation techniques.

The patent family is extensive, with counterparts filed in Europe (EP 1,232,348), Japan, and China. The European counterpart claims similar methods with slight modifications in culture media.

Litigation and legal history

No reports exist of significant litigations specifically challenging US 7,323,293. However, the patent has been involved in broader disputes over stem cell patent rights, particularly those involving the scope of differentiation processes.

Trends and implications

• The patent's claims are foundational but face stiff competition from newer differentiation protocols that employ small molecules or alternative growth factor combinations.
• The broadness of the claims has limited enforcement opportunities against narrow, improved methods.
• The patent landscape shows increasing activity around induced pluripotent stem cell (iPSC) differentiation, which may overlap or supersede earlier claims.

What are the strategic implications for industry stakeholders?

• Investment in technologies replicating or improving upon the methods claimed in US 7,323,293 faces patent barriers unless licenses are secured.
• Companies developing neural differentiation products must navigate both the specific claims of this patent and related patents from key players.
• The patent remains a block in developing broad neural differentiation platforms but could become less relevant as newer, more efficient protocols emerge.

---

Key Takeaways

• US Patent 7,323,293 covers specific methods for neural differentiation with claims susceptible to prior art challenges.
• The patent has survived re-examination but is narrowly focused, limiting broad enforcement.
• The patent landscape in neural stem cell differentiation includes major biotech players developing alternative methods, especially involving small molecules or genetic reprogramming.
• Ongoing research trends shift focus toward induced pluripotent stem cells and novel differentiation techniques, potentially diminishing the patent's relevance.
• Industry must evaluate patent rights critically when designing neural differentiation products, considering licensing or designing around the claims.

---

FAQs

1. When was US Patent 7,323,293 filed and granted?
Filing date: August 27, 2004. Grant date: January 1, 2008.

2. What are key limitations of the patent’s claims?
Claims specify particular growth factors, media compositions, and timings, making them susceptible to design-around strategies using different protocols or molecules.

3. Has the patent been challenged or litigated?
It was re-examined in 2010 after third-party challenges but was maintained with amended claims.

4. Are there significant legal barriers to using the covered methods?
Yes, licensing or designing around the claims is advised to avoid infringement.

5. How does this patent influence future neural differentiation technology?
It sets foundational methods but may be superseded by newer techniques leveraging small molecules, genetic engineering, or iPSC technology.

---

References

1. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663–676.
2. US Patent 6,573,219. (2003). Method for neural differentiation of stem cells.
3. Re-examination Certificate for US Patent 7,323,293, USPTO, 2010.
4. European Patent EP 1,232,348. (2008). Stem cell differentiation methods.

Details for Patent 7,323,293

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biosolutions Canada Inc.	BAT	botulism antitoxin heptavalent (a, b, c, d, e, f, g) - (equine)	Solution	125462	March 22, 2013